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Validity of the Stent Thrombosis Risk Score in
Predicting Early Stent Thrombosis after Primary
Percutaneous Coronary Intervention
Rajesh Kumar*, Sahar Tariq, Madiha Fatima, Tahir Saghir, Mahesh Kumar Batra,
Musa Karim, Jawaid Akbar Sial, Naveedullah Khan, Syed Nadeem Hasan Rizvi
National Institute of Cardiovascular Diseases (NICVD), Karachi, Pakistan

Abstract
Background: The thrombosis of the stent is one of the most important complications of percutaneous interventions,
resulting in complete occlusion of the stented vessel. Aim of this study was to determine the validity of Stent Thrombosis Risk Score (STRS) in predicting early stent thrombosis (ST) after primary Percutaneous Coronary Intervention
(PCI).
Methods: For this study, 569 consecutive patients undergone primary PCI from July 2018 to December 2018 were
recruited. Early ST was deﬁned as ST occurred during or within 30 days after the procedure. The STRS was calculated as
proposed, developed, and validated in a past study. The receiver operating characteristic curve analysis was performed
to determine the optimal cut-off value and area under the curve (AUC).
Results: A total of 569 patients were included, the median age was 56 [61e50] years. Early ST was observed in 33 (5.8%)
patients. The median STRS was 4 [5e3] vs. 3 [4e2]; p ¼ 0.009 for patients with and without Early ST respectively. STRS
was found to be an independent predictor of early ST with an adjusted odds ratio of 1.41 (1.02e1.95). AUC was 0.631 and
the optimal cut-off value was ≥5. Early ST rate was 3.3% at STRS of 0e2, which raised to 5.0% at STR of 3e4, and 17.2%
at STRS of ≥5.
Conclusions: In conclusion, STRS was found to be an independent predictor of early ST after primary PCI and has
signiﬁcant discriminating power. The rate of early stent thrombosis after primary PCI exponentially increased at STRS
cut-off value of ≥5.
Keywords: Percutaneous coronary interventions, Stent thrombosis, Risk score, Validity, Predictive value

1. Introduction

W

orldwide, the incidence and prevalence
of cardiovascular diseases vary depending upon the multiple factors including socioeconomic status, health care systems, etc. but we
are lacking precise data so far. Among cardiovascular diseases, acute coronary syndrome
(ACS) is one of the major causes of morbidity and
mortality [1]. Current guidelines suggest that the
patients, who present with ACS, speciﬁcally ST-

segment elevation myocardial infarction (STEMI),
must be gone through primary percutaneous
intervention (PCI) emergently to reduce both
mortality and morbidity [2]. Like any other
intervention procedure, primary PCI has its own
complications and thrombosis of the stent is the
most important one resulting in complete occlusion of the stented vessel. A large prospective
study, Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction
(HORIZONS-AMI), showed the overall rate of
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stent thrombosis at 30 days between 1.9% and
2.5% [3], that was considerably higher than 0.1%e
0.6% early stent thrombosis rates in patients with
stable coronary artery disease, observed from the
randomized controlled trials of DES [4],[5] and
also higher than that was observed in high and
moderate risk patients with non-STEMI in the
Acute Catheterization and Urgent Intervention
Triage Strategy (ACUITY) trial, i.e early ST rate of
1.5% [6].
Over the past several years, many researchers
have investigated potential predictors of stent
thrombosis especially acute and sub-acute categories and identiﬁed a number of angiographic,
clinical, procedural and post-procedural risk factors
of stent thrombosis [7e10]. Dangas et al. [11]
formulated a stent thrombosis risk score to stratify
the patients at higher risk of stent thrombosis after
pPCI. This potentially useful proposed risk assessment tool has never been validated for setting other
than development settings. Therefore, aim of our
study was to determine the validity of the Stent
Thrombosis Risk Score in Predicting Early Stent
Thrombosis after pPCI in our setting.

2. Materials and methods
The ethical review committee approval and
permission were taken to access the institutional STsegment elevation myocardial infarction (STEMI)
database of the National Institute of Cardiovascular
Diseases (NICVD), Karachi, Pakistan. Hospital records were obtained for the consecutive patients
who went through primary PCI for STEMI from July
2018 to December 2018. As an institutional practice,
written informed consent before the procedure was
obtained from all the patients regarding the use of
data obtained from hospital records for research
purposes. And records of the patients who refused
to give consent were inaccessible to the researcher.
The primary PCI procedures were performed by the
consultant cardiologists culprit artery was attempted and staged PCI was planned wherever needed.
Conventional stenting technique i.e. stenting followed by post-dilation of stent with NC balloon. No
complex procedures were done considering the
setting of primary PCI and the need for timely
restoration of TIMI ﬂow to avoid ischemic myocardial injury.
All patients in our study were preloaded with
soluble aspirin (300 mg), Clopidogrel (600 mg),
unfractionated Heparin as bolus (body-weight
adjusted dose of 70e100units/kg) and glycoprotein
IIb/IIIa inhibitor i.e. tiroﬁban as bolus dose during
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the procedure. Glycoprotein IIb/IIIa inhibitor (tiroﬁban) as IV infusion in patients with high
thrombus burden and short ischemic time. All these
patients were prescribed with dual antiplatelet
therapy (DAPT) for a one-month duration and
Clopidogrel for 12 months duration and aspirin indeﬁnite period of time.
Patients' demographic characteristics, cardiac risk
proﬁle, angiographic characteristics, and in-hospital
outcomes were obtained from the hospital record of
the patients. Along with the ongoing institution
quality controls intact, information of all the
included patients, available in the institutional
electronic database were veriﬁed by the patient's
physical ﬁle and angiographic ﬁlms and discrepancies, when found, were addressed appropriately.
Early stent thrombosis (ST) included ST during
the procedure or within 30 days after the procedure.
The deﬁnition proposed by the Academic Research
Consortium was used to classify stent thrombosis
[12]. Data regarding ST during the procedure and
during the hospital stay after the procedure were
obtained from the hospital recorded. And a telephonic follow-up was made to obtain data regarding
ST within 30 days after the procedure. Verbal consent was obtained during telephonic follow-up.
The Stent Thrombosis Risk Score was calculated
as proposed by Dangas GD et al. [11], it is a practical
risk score in predicting the risk of early stent
thrombosis (ST) after PCI for ACS. Variables
included in this risk score were baseline platelet
count, insulin-dependent diabetes mellitus, baseline
thrombolysis in myocardial infarction (TIMI) ﬂow
grade 0-I, early anticoagulant therapy (pre-PCI),
ulcerated or aneurysmal lesion, number of treated
vessels, and ﬁnal TIMI ﬂow grade<III. The scoring
schema for the calculation of the Stent Thrombosis
Risk Score is presented in Fig. 1. Ulcerated or
aneurysmal lesions were classiﬁed based on angiographic morphology proposed by Ambrose JA et al.
[13]
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Fig. 1. Scoring schema for the calculation of the Stent Thrombosis Risk Score.11

At a 95% conﬁdence level and 5% margin of error,
the sample size for the study was calculated with an
expected AUC (area under the curve) of 0.67 for ST
risk score in predicting early ST [11]. A minimum
sample size of n ¼ 230 was calculated and a design
factor of 2.25 was considered in order to address loss
to follow-up and other biases, under these considerations a sample size of 518 was calculated to be
sufﬁcient for the study.
Data analysis was executed using IBM SPSS Statistics for Windows, Version 21.0. (IBM Corp.,
Armonk, NY, US). The KolmogoroveSmirnov test
was applied to evaluate the normality of distribution
of continuous variables such age (years), length of
lesion (mm), length of stent (mm), and diameter of
stent. And appropriate t-test or ManneWhitney U
test was applied for the between-group comparison
in univariate analysis and the Chi-square or Fisher
exact test was applied for the categorical response
variables. Multivariate logistic regression analysis
was performed for early ST with signiﬁcant variables from univariate analysis and clinically significant variables as explanatory variables. Odds ratio
[95% conﬁdence interval] were reported for the logistic regression analysis. To ﬁnd out the area under
the curve (AUC) and optimal cut-off value, Receiver
operating characteristic (ROC) curve analysis was
performed. The optimal cut-off value of stent
thrombosis risk score was computed with the help
of the Youden Index. Patients were stratiﬁed based
on the optimal cut-off value and sensitivity, speciﬁcity, and accuracy were calculated. Criteria for
statistical signiﬁcance was P-value of 0.05.

3. Results
A total of 569 patients undergone primary PCI
were included, the median age of the patient was 56
[61e50] years. Early stent thrombosis (within 30
days of the procedure) was observed in 33 (5.8%) of
the patients. The hypothesis of normality of distribution of age (years), lesion length (mm), stent
length (mm), and stent diameter were rejected with
KolmogoroveSmirnov test p-value of <0.001. On
univariate analysis diabetes, hypertension, and
Killip class III-IV at presentation were found to be
related to the development of early ST after primary
PCI. Baseline clinical and demographic characteristics and univariate analysis for stent thrombosis
are presented in Table 1.
The computed Stent Thrombosis Risk Score was
considerably higher among the patients with early
ST as compared to the patients without early ST, the
median score was 4 [5e3] vs. 3 [4e2]; p ¼ 0.009
respectively. Individual parameters of stent thrombosis risk score (STRS) by early ST are presented in
Table 2.
The multivariate binary logistic regression analysis for early stent thrombosis is presented in Table
3. Among the clinically signiﬁcant factors, Killip
Class III-IV at presentation and Stent Thrombosis
Risk Score were found to be independent predictors
of early stent thrombosis with adjusted odds ratio
[95% CI] of 4.24 [1.39e12.92] and 1.41 [1.02e1.95]
respectively.
The distribution of Stent Thrombosis Risk Score,
ROC curve, and subsequent rate of early stent

Table 1. Baseline clinical and demographic characteristics and univariate analysis for stent thrombosis.
Characteristics

Total

N
Male
Age (years)
Diabetes mellitus
Hypertension
Smoking
Obesity
Positive family history
Killip Class (III-IV)
Left dominance
Multivessel disease (MVD)
Lesion length (mm)
Bare-metal stent (BMS)
Stent length (mm)
Stent diameter (mm)
Stent Thrombosis Risk Score

Early Stent Thrombosis

569
458 (80.5%)
56 [61e50]
152 (26.7%)
232 (40.8%)
134 (23.6%)
77 (13.5%)
21 (3.7%)
24 (4.2%)
51 (9%)
339 (59.6%)
16 (24e13)
301 (52.9%)
15 (18e12)
3.5 (3.5e3)
3 (4e2)

thrombosis by risk score are presented in Fig. 2. The
area under the curve (AUC) of Stent Thrombosis
Risk score to predict the early stent thrombosis is
0.631 (0.524e0.738), based on Youden's index the
optimal cut-off value was 5 with an accuracy of
88%, speciﬁcity of 91%, and sensitivity of 30%. Early
stent thrombosis was found to be linearly associated
with the risk score, early ST rate was 3.3% for the
patients with the risk score of 0e2, which raised to
Table 2. Individual parameters of stent thrombosis risk score (STRS) by
early ST.
Characteristics

Total

Early Stent Thrombosis
No

P-value

Yes

N
569
536
33
Baseline platelet count, K/ml
<250
218 (38.3%) 206 (38.4%) 12 (36.4%)
250 to 400
302 (53.1%) 288 (53.7%) 14 (42.4%)
>400
49 (8.6%)
42 (7.8%)
7 (21.2%)
History of insulin-dependent diabetes mellitus (IDDM)
Yes
14 (2.5%)
11 (2.1%)
3 (9.1%)
No
555 (97.5%) 525 (97.9%) 30 (90.9%)
Baseline TIMI ﬂow grade of 0-I
Yes
393 (69.1%) 366 (68.3%) 27 (81.8%)
No
176 (30.9%) 170 (31.7%) 6 (18.2%)
Early anticoagulant therapy
Yes
569 (100%)
536 (100%)
33 (100%)
No
0 (0%)
0 (0%)
0 (0%)
Aneurysm or ulceration
Yes
0 (0%)
0 (0%)
0 (0%)
No
569 (100%)
536 (100%)
33 (100%)
Number of vessels treated
<2
569 (100%)
536 (100%)
33 (100%)
2
0 (0%)
0 (0%)
0 (0%)
3
0 (0%)
0 (0%)
0 (0%)
Final TIMI ﬂow grade of 0-II
Yes
22 (3.9%)
20 (3.7%)
2 (6.1%)
No
547 (96.1%) 516 (96.3%) 31 (93.9%)

P-value

No

Yes

536
431 (80.4%)
56 [61e49]
138 (25.7%)
212 (39.6%)
128 (23.9%)
73 (13.6%)
18 (3.4%)
18 (3.4%)
48 (9%)
319 (59.5%)
16 (24e13)
285 (53.2%)
15 (18e12)
3.5 (3.5e3)
3 (4e2)

33
27 (81.8%)
56 [66e50]
14 (42.4%)
20 (60.6%)
6 (18.2%)
4 (12.1%)
3 (9.1%)
6 (18.2%)
3 (9.1%)
20 (60.6%)
20 (25e14)
16 (48.5%)
15 (22e15)
3 (3.5e2.75)
4 (5e3)

e
0.843
0.256
0.036*
0.017*
0.454
0.807
0.09
<0.001*
0.979
0.901
0.281
0.601
0.293
0.1
0.009*

5.0% with the risk score of 3e4, and 17.2% of the risk
score of 5.

4. Discussion
The principal ﬁndings from this study of 569 patients with STEMI are, a higher Stent Thrombosis
Risk Score index was associated with the higher risk
of early stent thrombosis which was 3.3% for the
patients with risk score of 0e2, which raised to 5.0%
with the risk score of 3e4, and 17.2% of the risk
score of 5.
Overall rate of ST (5.8%) in our study was relatively higher than some of the past studies [3e6],
[14e16], a recently published data by Tariq S et al.

0.027

0.011

0.103
e
e
e

0.501

Table 3. Multivariate binary logistic regression analysis for early stent
thrombosis.
Characteristics

Odds Ratio 95% confidence p-value
(OR)
interval

Male
Age (years)
Diabetes mellitus
Hypertension
Smoking
Obesity
Positive family history
Killip Class (III-IV)
Left dominance
Multivessel disease (MVD)
Lesion length (mm)
Bare-metal stent (BMS)
Stent length (mm)
Stent diameter (mm)
Stent Thrombosis Risk Score

1.87
1.02
1.76
1.88
0.72
0.78
1.9
4.24
0.73
0.73
1
1.01
1.02
0.73
1.41

0.67e5.24
0.99e1.06
0.79e3.94
0.84e4.2
0.27e1.91
0.25e2.46
0.44e8.17
1.39e12.92
0.18e2.89
0.33e1.63
0.94e1.05
0.45e2.27
0.96e1.08
0.4e1.35
1.02e1.95

0.234
0.177
0.168
0.122
0.515
0.675
0.389
0.011*
0.652
0.446
0.865
0.988
0.464
0.319
0.037*

Dependent variable: Early stent thrombosis Hosmer and Lemeshow Test (chi-square ¼ 15.747, df ¼ 8, p ¼ 0.046).
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Fig. 2. Distribution of Stent Thrombosis Risk Score (A), ROC curve (B), subsequent rate of early stent thrombosis by risk score (C and D).

[17] for the same population reported that prescribing DAPT (Clopidogrel and Aspirin) on
discharge is strongly and inversely associated with
rate of early ST. The importance of DAPT is well
established and non-compliance to the DAPT therapy due to lack of awareness could be one of the
cause of high rates of ST in our population. However, premature discontinuation or non-compliance
to the DAPT was out of the score of this research
and future studies are warranted in this regards.
Several studies have identiﬁed different predictors of early stent thrombosis. Mosca et al.
identiﬁed some factors related to the higher risk of
developing stent thrombosis including presentation
as a STEMI and anteroseptal infarction on ECG,
female gender and patients already on clopidogrel
prior to primary PCI [18]. Iakovou et al. identiﬁed
premature discontinuation of DAPT, bifurcation lesions, renal failure, low ejection fraction, diabetes
and, for sub-acute thrombosis, stent length as predictors of stent thrombosis [19]. The EXAMINATION trial identiﬁed a lower ejection fraction and
worse Killip class at discharge, older age, lack of STsegment resolution of at least 70%, BMS

implantation at the index procedure as predictors of
stent thrombosis [20].
Dangas et al. [12] formulated and validated a risk
score for ST which can be used in routine and it was
all grounded on a pooled analysis of patients undergoing PCI with stent implantation in the two
large trials, HORIZAN-AMI and ACUITY. They
found that with increasing risk score index values,
there is a signiﬁcant rise in ST rates, which is also
statistically signiﬁcant in both the development as
well as the validation datasets. In this study area
under the curve (AUC) of ST risk score in predicting
early ST was reported to be 0.76 and 0.67 in development and validation cohort respectively. Our aim
was to determine the validity of the Stent Thrombosis Risk Score in our population. These ﬁndings
were consistent with our study, in our study, AUC of
Stent Thrombosis Risk score for the prediction of
early stent thrombosis was found to be 0.631. Based
on ROC analysis the optimal cut-off value for early
stent thrombosis was 5 with an accuracy of 88%,
speciﬁcity of 91%, and sensitivity of 30%. The score
was found to be linearly associated with the risk
score, early ST rate was 3.3% for the patients with

the risk score of 0e2, which raised to 5.0% with the
risk score of 3e4, and 17.2% of the risk score of 5.
Stent Thrombosis Risk Score was established as
an independent predictor of early stent thrombosis
with an adjusted odds ratio (95% CI) of 1.41
(1.02e1.95) along with Killip Class III-IV at presentation 4.24 (1.39e12.92). Hence, Stent Thrombosis
Risk score is a practical approach, with statistically
signiﬁcant predictive strength, for the early stent
thrombosis risk stratiﬁcation after primary PCI. It
comprises of seven readily available and simple
variables and it can be easily adopted in clinical
practice and investigation in the setting of acute STSegment Elevation Myocardial Infarction (STEMI).
To the best of our knowledge, this is the ﬁrst study
to assess the validity of stent thrombosis risk score
other than development setting. However, our study
has few limitations, ﬁrst patients for this study were
recruited retrospectively from hospital records, and
secondly, we only considered patients who underwent primary PCI, early invasive or non-emergent
PCI were not included, thirdly, small sample size,
and ﬁnally, the data regarding study outcome were
obtained on telephonic follow-up. Implanted stent
type and subtypes were reported to be associated
with varying ranges of rate of ST in various studies,
therefore, further studies are warranted to address
the validity of Stent Thrombosis Risk Score for
various types and subtypes of stents.

5. Conclusion
In conclusion, our study has demonstrated that
the Stent Thrombosis Risk Score (STRS) was found
to be an independent predictor of early stent
thrombosis (ST) after primary PCI and has statistically signiﬁcant discriminating power. Early ST rate
after primary PCI exponentially increased at STRS
cut-off value of 5 or higher. Therefore, STRS can be
used for the risk stratiﬁcation of early ST after primary PCI.
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